Form: Injection – syringe
Strength: 300mg / 2mL
Supply: 1 pack (2 syringes each)

Dupixent is a monoclonal antibody that targets two specific proteins, interleukin-4 (IL-4) and interleukin-13 (IL-13), and has been approved for treatment of moderate-to-severe atopic dermatitis in adults and children aged six and older, as well as moderate-to-severe asthma in patients aged 12 years and above. Dupixent has been proven to significantly reduce the severity and extent of skin lesions, itching, and inflammation in atopic dermatitis patients and significantly reduce the frequency and severity of asthma exacerbations in those with asthma. Dupixent has several advantages over traditional asthma therapies and has a favorable safety profile. The medication offers a new treatment option that targets the underlying pathophysiological mechanisms of chronic inflammatory diseases, leading to better outcomes and improved quality of life.